Fresenius Medical Care AG (FMS)
20.11
-1.31
(-6.12%)
USD |
NYSE |
May 07, 16:00
20.12
+0.01
(+0.05%)
After-Hours: 20:00
Fresenius Medical Care Revenue (Quarterly): 5.371B for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 5.132B |
December 31, 2023 | 5.371B |
September 30, 2023 | 5.375B |
June 30, 2023 | 5.262B |
March 31, 2023 | 5.053B |
December 31, 2022 | 5.109B |
September 30, 2022 | 5.134B |
June 30, 2022 | 5.067B |
March 31, 2022 | 5.104B |
December 31, 2021 | 5.315B |
September 30, 2021 | 5.237B |
June 30, 2021 | 5.207B |
March 31, 2021 | 5.073B |
December 31, 2020 | 5.246B |
September 30, 2020 | 5.161B |
June 30, 2020 | 5.019B |
March 31, 2020 | 4.952B |
December 31, 2019 | 5.072B |
September 30, 2019 | 4.914B |
June 30, 2019 | 4.881B |
March 31, 2019 | 4.694B |
December 31, 2018 | 4.906B |
September 30, 2018 | 4.718B |
June 30, 2018 | 5.031B |
March 31, 2018 | 4.884B |
Date | Value |
---|---|
December 31, 2017 | 5.215B |
September 30, 2017 | 5.097B |
June 30, 2017 | 4.919B |
March 31, 2017 | 4.845B |
December 31, 2016 | 4.765B |
September 30, 2016 | 4.701B |
June 30, 2016 | 4.548B |
March 31, 2016 | 4.320B |
December 31, 2015 | 4.862B |
September 30, 2015 | 4.179B |
June 30, 2015 | 4.137B |
March 31, 2015 | 4.126B |
December 31, 2014 | 4.930B |
September 30, 2014 | 4.295B |
June 30, 2014 | 3.855B |
March 31, 2014 | 3.550B |
December 31, 2013 | 3.565B |
September 30, 2013 | 3.601B |
June 30, 2013 | 3.627B |
March 31, 2013 | 3.571B |
December 31, 2012 | 3.338B |
September 30, 2012 | 3.328B |
June 30, 2012 | 3.477B |
March 31, 2012 | 3.193B |
December 31, 2011 | 3.836B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.881B
Minimum
Jun 2019
5.375B
Maximum
Sep 2023
5.134B
Average
5.121B
Median
Revenue (Quarterly) Benchmarks
Biodexa Pharmaceuticals Plc | -- |
NuCana PLC | -- |
TC BioPharm (Holdings) PLC | -- |
DaVita Inc | 3.071B |
Bicycle Therapeutics PLC | 19.53M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 202.38M |
Total Expenses (Quarterly) | 4.690B |
EPS Diluted (Quarterly) | 0.3446 |
Enterprise Value | 20.94B |
Gross Profit Margin (Quarterly) | 27.06% |
Profit Margin (Quarterly) | 3.77% |
Earnings Yield | 4.57% |
Operating Earnings Yield | 14.06% |
Normalized Earnings Yield | 4.952 |